Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.
A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.
Simmon
Vincent F
VF
D065094:Bradykinin B2 Receptor Antagonists; D001930:Brain Injuries / Q000188:drug therapy*; D006801:Humans; D010919:Placebos; D011804:Quinolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D065094:Bradykinin B2 Receptor Antagonists; C403051:LF 16-0687; D010919:Placebos; D011804:Quinolines